Sanofi is halting a clinical trial aimed at getting another indication approved for its key heart drug Multaq after it saw increased cardiovascular problems among patients taking the drug.
Sanofi is halting a clinical trial aimed at getting another indication approved for its key heart drug Multaq after it saw increased cardiovascular problems among patients taking the drug.